account of Coltrane's life and that of Mr. Porter's. There are some issues which need further work to resolve. It appears that Mr. Porter's claims that he corrected "numerous errors" are not supportable by the evidence. Particularly egregious is his misinformation about liver cancer. I would have been delighted to have been given the opportunity to assist him and help him in any way possible. But he chose to make his claims of errors without checking with those who came before him. Therefore, within the pages of John Coltrane: His Life and Music new errors have been created and resolvable issues have been left unresolved. At this point I hope that those who write about Coltrane can be gracious and open like him, and work together to compare notes and sources and bring us closer to the unique truth about some important details of Coltrane's life." Dr. Porter's response to Dr. Simpkins was published in 2004. In 2009 the Jazz Archive at Duke University announced the acquisition and availability of the tapes of interviews Dr. Simpkins had conducted in the course of doing research for his biography of John Coltrane. The interviews were conducted between 1971 and 1974. They include a spoken record of those who knew Coltrane as well as numerous contributors to the development of modern Jazz. Patents for Phospholipid Nanoparticle-Based Cardiovascular Support Fluid Since his departure from LSU Health Sciences Center Simpkins has focused on the development of his biotechnology company, Vivacelle Bio founded in 2013. The company web page is vivacellebio.com. Vivacelle Bio, Inc. was organized for the purpose of commercializing a new resuscitation fluid, developed by Dr. Simpkins, that is based on phospholipid nanoparticles. His experiments showed that this resuscitation fluid, named VBI-1, could be used safely to replace most of the circulating blood volume. His experiments, in collaboration with physicist Juan Rodriguez, also showed that this resuscitation fluid readily absorbed nitric oxide. Moreover, in animal experiments, VBI-1 was superior to the standard, Ringer's lactate in reversing hypovolemia after blood loss and restoring the blood pressure. On November 22, 2011, Simpkins was granted his first patent, US patent #8063020. This fluid is designed to promote survival after hypovolemic shock for any reason such as blood loss, massive infection, neurological injury, acute radiation injury, burns or childhood diarrhea. At this point, the blood substitutes, blood products, hetastarch based colloids, albumin and hypertonic solutions have all been